The Spatial Distribution of Star Formation in the Solar Neighbourhood: Do all stars form in clusters?

We present a global study of low mass, young stellar object (YSO) surface densities in nearby (< 500 pc) star forming regions based on a comprehensive collection of Spitzer Space Telescope surveys. We show that the distribution of YSO surface densities in the solar neighbourhood is a smooth distribution, being adequately described by a lognormal function from a few to 10^3 YSOs per pc^2, with a peak at 22 stars/pc^2 and a dispersion of 0.85. We do not find evidence for multiple discrete modes of star-formation (e.g. clustered and distributed). Comparing the observed surface density distribution to previously reported surface density threshold definitions of clusters, we find that the fraction of stars in clusters is crucially dependent on the adopted definitions, ranging from 40 to 90%. However, we find that only a low fraction (< 26%) of stars are formed in dense environments where their formation/evolution (along with their circumstellar disks and/or planets) may be affected by the close proximity of their low-mass neighbours.Comment: 6 pages, 2 figures, MNRAS letters, accepte

Students` perceptions of study modes

This paper reports on a survey of how Australian undergraduate students perceive the benefits of broad study modes: face-to-face classes, web-based study, and print-based study. Two benefit types were identified through factor analysis: engagement and functionality. Respondents rated face-to-face classes highest on engagement and print-based study highest on functionality. However, they distinguished only marginally between the engagement and functionality benefits of print-based and web-based study. Two variables associated with differences in students\u27 perceptions of study modes were attendance mode and student tenure. The findings raise questions about the learning and marketing rationales for offering web-based delivery of educational programmes at the expense of both the traditional face-to-face experience and the traditional &ldquo;distance&rdquo; experience in Australia using print materials. <br /

The Nuclear Astrophysics program at n-TOF (CERN)

An important experimental program on Nuclear Astrophysics is being carried out at the n-TOF since several years, in order to address the still open issues in stellar and primordial nucleosynthesis. Several neutron capture reactions relevant to s-process nucleosynthesis have been measured so far, some of which on important branching point radioisotopes. Furthermore, the construction of a second experimental area has recently opened the way to challenging measurements of (n, charged particle) reactions on isotopes of short half-life. The Nuclear Astrophysics program of the n-TOF Collaboration is here described, with emphasis on recent results relevant for stellar nucleosynthesis, stellar neutron sources and primordial nucleosynthesis

Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries : Analysis from the RIETE registry

publishersversionPeer reviewe

Investigation of the Pu 240 (n,f) reaction at the n_TOF/EAR2 facility in the 9 meV-6 MeV range

Background: Nuclear waste management is considered amongst the major challenges in the field of nuclear energy. A possible means of addressing this issue is waste transmutation in advanced nuclear systems, whose operation requires a fast neutron spectrum. In this regard, the accurate knowledge of neutron-induced reaction cross sections of several (minor) actinide isotopes is essential for design optimization and improvement of safety margins of such systems. One such case is Pu240, due to its accumulation in spent nuclear fuel of thermal reactors and its usage in fast reactor fuel. The measurement of the Pu240(n,f) cross section was previously attempted at the CERN n_TOF facility EAR1 measuring station using the time-of-flight technique. Due to the low amount of available material and the given flux at EAR1, the measurement had to last several months to achieve a sufficient statistical accuracy. This long duration led to detector deterioration due to the prolonged exposure to the high α activity of the fission foils, therefore the measurement could not be successfully completed. Purpose: It is aimed to determine whether it is feasible to study neutron-induced fission at n_TOF/EAR2 and provide data on the Pu240(n,f) reaction in energy regions requested for applications. Methods: The study of the Pu240(n,f) reaction was made at a new experimental area (EAR2) with a shorter flight path which delivered on average 30 times higher flux at fast neutron energies. This enabled the measurement to be performed much faster, thus limiting the exposure of the detectors to the intrinsic activity of the fission foils. The experimental setup was based on microbulk Micromegas detectors and the time-of-flight data were analyzed with an optimized pulse-shape analysis algorithm. Special attention was dedicated to the estimation of the non-negligible counting loss corrections with the development of a new methodology, and other corrections were estimated via Monte Carlo simulations of the experimental setup. Results: This new measurement of the Pu240(n,f) cross section yielded data from 9meV up to 6MeV incident neutron energy and fission resonance kernels were extracted up to 10keV. Conclusions: Neutron-induced fission of high activity samples can be successfully studied at the n_TOF/EAR2 facility at CERN covering a wide range of neutron energies, from thermal to a few MeV

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

Background Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. Methods Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. Results A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55). Conclusions Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.

Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)

Background: This study provides a global overview of the management of patients with acute cholecystitis during the initial phase of the COVID-19 pandemic. Methods: CHOLECOVID is an international, multicentre, observational comparative study of patients admitted to hospital with acute cholecystitis during the COVID-19 pandemic. Data on management were collected for a 2-month study interval coincident with the WHO declaration of the SARS-CoV-2 pandemic and compared with an equivalent pre-pandemic time interval. Mediation analysis examined the influence of SARS-COV-2 infection on 30-day mortality. Results: This study collected data on 9783 patients with acute cholecystitis admitted to 247 hospitals across the world. The pandemic was associated with reduced availability of surgical workforce and operating facilities globally, a significant shift to worse severity of disease, and increased use of conservative management. There was a reduction (both absolute and proportionate) in the number of patients undergoing cholecystectomy from 3095 patients (56.2 per cent) pre-pandemic to 1998 patients (46.2 per cent) during the pandemic but there was no difference in 30-day all-cause mortality after cholecystectomy comparing the pre-pandemic interval with the pandemic (13 patients (0.4 per cent) pre-pandemic to 13 patients (0.6 per cent) pandemic; P = 0.355). In mediation analysis, an admission with acute cholecystitis during the pandemic was associated with a non-significant increased risk of death (OR 1.29, 95 per cent c.i. 0.93 to 1.79, P = 0.121). Conclusion: CHOLECOVID provides a unique overview of the treatment of patients with cholecystitis across the globe during the first months of the SARS-CoV-2 pandemic. The study highlights the need for system resilience in retention of elective surgical activity. Cholecystectomy was associated with a low risk of mortality and deferral of treatment results in an increase in avoidable morbidity that represents the non-COVID cost of this pandemic